vs
Side-by-side financial comparison of Global Business Travel Group, Inc. (GBTG) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Global Business Travel Group, Inc. is the larger business by last-quarter revenue ($792.0M vs $761.7M, roughly 1.0× Insulet Corporation). Insulet Corporation runs the higher net margin — 12.0% vs 10.5%, a 1.5% gap on every dollar of revenue. On growth, Global Business Travel Group, Inc. posted the faster year-over-year revenue change (34.0% vs 33.9%). Insulet Corporation produced more free cash flow last quarter ($89.5M vs $13.0M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (24.9% CAGR vs 13.9%).
A travel management company (TMC) is a travel agency which manages organizations' corporate or business travel programs. Such companies will often provide an end-user online booking tool, mobile application, program management, and consulting teams, executive travel services, meetings and events support, reporting functionality, duty of care, and more. Non-Profit travel management companies also provide services to manage complex visa requirements, pre-trip medical needs, remote area travel, ...
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
GBTG vs PODD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $792.0M | $761.7M |
| Net Profit | $83.0M | $91.1M |
| Gross Margin | — | 69.5% |
| Operating Margin | 3.7% | 16.0% |
| Net Margin | 10.5% | 12.0% |
| Revenue YoY | 34.0% | 33.9% |
| Net Profit YoY | 692.9% | 157.3% |
| EPS (diluted) | $0.16 | $1.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $761.7M | ||
| Q4 25 | $792.0M | $783.7M | ||
| Q3 25 | $674.0M | $706.3M | ||
| Q2 25 | $631.0M | $649.1M | ||
| Q1 25 | $621.0M | $569.0M | ||
| Q4 24 | $591.0M | $597.5M | ||
| Q3 24 | $597.0M | $543.9M | ||
| Q2 24 | $625.0M | $488.5M |
| Q1 26 | — | $91.1M | ||
| Q4 25 | $83.0M | $101.6M | ||
| Q3 25 | $-62.0M | $87.6M | ||
| Q2 25 | $15.0M | $22.5M | ||
| Q1 25 | $75.0M | $35.4M | ||
| Q4 24 | $-14.0M | $100.7M | ||
| Q3 24 | $-128.0M | $77.5M | ||
| Q2 24 | $27.0M | $188.6M |
| Q1 26 | — | 69.5% | ||
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% |
| Q1 26 | — | 16.0% | ||
| Q4 25 | 3.7% | 18.7% | ||
| Q3 25 | 1.8% | 16.7% | ||
| Q2 25 | 5.4% | 18.7% | ||
| Q1 25 | 8.9% | 15.6% | ||
| Q4 24 | 5.1% | 18.3% | ||
| Q3 24 | 4.5% | 16.2% | ||
| Q2 24 | 6.7% | 11.2% |
| Q1 26 | — | 12.0% | ||
| Q4 25 | 10.5% | 13.0% | ||
| Q3 25 | -9.2% | 12.4% | ||
| Q2 25 | 2.4% | 3.5% | ||
| Q1 25 | 12.1% | 6.2% | ||
| Q4 24 | -2.4% | 16.9% | ||
| Q3 24 | -21.4% | 14.2% | ||
| Q2 24 | 4.3% | 38.6% |
| Q1 26 | — | $1.30 | ||
| Q4 25 | $0.16 | $1.42 | ||
| Q3 25 | $-0.13 | $1.24 | ||
| Q2 25 | $0.03 | $0.32 | ||
| Q1 25 | $0.16 | $0.50 | ||
| Q4 24 | $-0.04 | $1.38 | ||
| Q3 24 | $-0.28 | $1.08 | ||
| Q2 24 | $0.06 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $434.0M | $480.4M |
| Total DebtLower is stronger | $1.4B | $18.6M |
| Stockholders' EquityBook value | $1.6B | $1.3B |
| Total Assets | $4.9B | $3.0B |
| Debt / EquityLower = less leverage | 0.88× | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $480.4M | ||
| Q4 25 | $434.0M | — | ||
| Q3 25 | $427.0M | — | ||
| Q2 25 | $601.0M | — | ||
| Q1 25 | $552.0M | — | ||
| Q4 24 | $536.0M | — | ||
| Q3 24 | $524.0M | — | ||
| Q2 24 | $515.0M | — |
| Q1 26 | — | $18.6M | ||
| Q4 25 | $1.4B | $930.8M | ||
| Q3 25 | $1.4B | $934.9M | ||
| Q2 25 | $1.4B | $939.0M | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $1.4B | $1.3B | ||
| Q3 24 | $1.4B | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.5B | $1.4B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $1.1B | $1.1B | ||
| Q2 24 | $1.2B | $998.4M |
| Q1 26 | — | $3.0B | ||
| Q4 25 | $4.9B | $3.2B | ||
| Q3 25 | $4.8B | $3.0B | ||
| Q2 25 | $3.9B | $3.5B | ||
| Q1 25 | $3.8B | $3.5B | ||
| Q4 24 | $3.6B | $3.1B | ||
| Q3 24 | $3.8B | $3.0B | ||
| Q2 24 | $3.8B | $2.9B |
| Q1 26 | — | 0.01× | ||
| Q4 25 | 0.88× | 0.61× | ||
| Q3 25 | 0.91× | 0.68× | ||
| Q2 25 | 1.15× | 0.64× | ||
| Q1 25 | 1.23× | 1.21× | ||
| Q4 24 | 1.32× | 1.07× | ||
| Q3 24 | 1.26× | 1.21× | ||
| Q2 24 | — | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $52.0M | $113.8M |
| Free Cash FlowOCF − Capex | $13.0M | $89.5M |
| FCF MarginFCF / Revenue | 1.6% | 11.8% |
| Capex IntensityCapex / Revenue | 4.9% | 3.2% |
| Cash ConversionOCF / Net Profit | 0.63× | 1.25× |
| TTM Free Cash FlowTrailing 4 quarters | $104.0M | $415.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $113.8M | ||
| Q4 25 | $52.0M | $183.3M | ||
| Q3 25 | $71.0M | $125.7M | ||
| Q2 25 | $57.0M | $196.5M | ||
| Q1 25 | $53.0M | $63.8M | ||
| Q4 24 | $65.0M | $147.7M | ||
| Q3 24 | $85.0M | $98.5M | ||
| Q2 24 | $73.0M | $96.5M |
| Q1 26 | — | $89.5M | ||
| Q4 25 | $13.0M | $48.2M | ||
| Q3 25 | $38.0M | $100.1M | ||
| Q2 25 | $27.0M | $177.9M | ||
| Q1 25 | $26.0M | $51.5M | ||
| Q4 24 | $33.0M | $94.1M | ||
| Q3 24 | $59.0M | $71.8M | ||
| Q2 24 | $49.0M | $74.0M |
| Q1 26 | — | 11.8% | ||
| Q4 25 | 1.6% | 6.2% | ||
| Q3 25 | 5.6% | 14.2% | ||
| Q2 25 | 4.3% | 27.4% | ||
| Q1 25 | 4.2% | 9.1% | ||
| Q4 24 | 5.6% | 15.7% | ||
| Q3 24 | 9.9% | 13.2% | ||
| Q2 24 | 7.8% | 15.1% |
| Q1 26 | — | 3.2% | ||
| Q4 25 | 4.9% | 17.2% | ||
| Q3 25 | 4.9% | 3.6% | ||
| Q2 25 | 4.8% | 2.9% | ||
| Q1 25 | 4.3% | 2.2% | ||
| Q4 24 | 5.4% | 9.0% | ||
| Q3 24 | 4.4% | 4.9% | ||
| Q2 24 | 3.8% | 4.6% |
| Q1 26 | — | 1.25× | ||
| Q4 25 | 0.63× | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | 3.80× | 8.73× | ||
| Q1 25 | 0.71× | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 2.70× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GBTG
| Travel | $620.0M | 78% |
| Other | $172.0M | 22% |
PODD
| Omnipod | $515.6M | 68% |
| International Omnipod | $242.9M | 32% |
| Drug Delivery | $3.3M | 0% |
